<DOC>
	<DOCNO>NCT00895115</DOCNO>
	<brief_summary>RATIONALE : Vitamin E supplement may stop delay development prostate cancer patient risk prostate cancer prostate cancer . It yet know vitamin E regimen effective prevent prostate cancer . PURPOSE : This randomized phase I trial compare vitamin E supplement regimen see well work prevent cancer patient risk prostate cancer prostate cancer .</brief_summary>
	<brief_title>Vitamin E Supplements Preventing Cancer Patients Risk Prostate Cancer Who Have Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine effect tocopherol supplementation plasma urine level α- , γ- , δ-tocopherols , PSA , prostaglandin E_2 compare blood urine sample collect supplementation patient prostate cancer . - Test hypothesis supplementation reduce oxidative nitrosative stress measure plasma level F_2-isoprostane , C-reactive protein , 3-nitrotyrosine well urinary level 8-hydroxy-2-deoxyguanosine ( 8-OHdG ) . - Determine level α- , γ- , δ-tocopherols prostate tissue analyze immunohistochemically ( IHC ) cell proliferation , apoptosis , cyclooxygenase-2 , 8-OHdG , 3-nitropyrosine level prostate cancer/tissue slide . OUTLINE : Patients randomize 1 3 arm . - Arm I : Patients receive supplementation . - Arm II : Patients receive oral high γ-tocopherol vitamin E supplementation daily 1 week . - Arm III : Patients receive oral high γ-tocopherol vitamin E supplementation daily 2 week . Blood , urine , tissue sample collect periodically analyze oxidative/nitrosative stress marker ( i.e. , F2-isoprostane , 8-OHdG , 3-nitrotyrosine , prostaglandin E2 , C-reactive protein , PSA ) , biomarkers prostate tumor nontumorous tissue ( i.e. , 8-OHdG , 3-nitrotyrosine , cyclooxygenase-2 ) IHC , pharmacokinetics high-performance liquid chromatography .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Tocopherols</mesh_term>
	<mesh_term>Vitamin E</mesh_term>
	<mesh_term>Tocotrienols</mesh_term>
	<mesh_term>alpha-Tocopherol</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Meets one follow criterion : Abnormal digital rectal examination abnormal prostate specific antigen ( &gt; 4.0 ng/mL ) Obstructing prostate Biopsyproven prostate cancer Scheduled undergo prostate surgery ( i.e. , transurethral prostatectomy prostatectomy ) PATIENT CHARACTERISTICS : No uncontrolled diabetes , uncontrolled blood pressure , chronic congestive heart failure , history renal insufficiency No personal family history bleed disorder No known history problem absorb dietary fat ( e.g. , Crohn 's disease , cystic fibrosis ) PRIOR CONCURRENT THERAPY : More 2 week since prior NSAIDs corticosteroids No concurrent supplementation vitamin E ( multivitamin contain ≤ 60 IU vitamin E allow ) No concurrent colestipol orlistat No concurrent warfarin dicumarol</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>prostate cancer</keyword>
</DOC>